News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Foamix Pharma (FOMX) Reports Third Quarter 2016 Financial Results and Provides Business Update



11/16/2016 8:56:52 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

REHOVOT, Israel, Nov. 15, 2016 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) ("Foamix Pharmaceuticals" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today financial results for the three and nine months ended September 30, 2016.

Foamix

Clinical, business and corporate developments for the three months ended September 30, 2016 and to date:

  • Target enrollment for the ongoing Phase 3 trials of FMX101 in patients with moderate-to-severe acne (900 patients) has been reached.
    • Additional over-enrollment of patients will continue to accommodate those patients who currently are in the screening process for the two (2) Phase 3 clinical trials. 
    • Final patient enrollment is expected to be complete by end of November 2016.
    • The Company expects to release topline results during the first half of 2017.
  • The Phase 2 for FMX103 in patients with papulopustular rosacea was completed in September 2016, four months ahead of the planned schedule. FMX103 demonstrated high clinically and statistically significant efficacy in treating moderate-to-severe rosacea, and it appeared to be safe and well tolerated.
  • U.S. Sales of Finacea® Foam, azelaic acid 15% for the treatment of rosacea, continue to grow.
    • Based on sales of Finacea® Foam reported by Bayer HealthCare AG for Q3, 2016 Foamix is entitled to royalty payments of $794,000, up 6% from the second quarter of 2016.
    • Foamix is also entitled to additional contingent payments totaling $1.75 million, due to Bayer's achievement of net sales in excess of the target set for this product.
    • Finacea® Foam was developed through a research and development collaboration between Foamix and Bayer, utilizing Foamix's proprietary foam technology platform. The drug was launched by Bayer in the USA in September, 2015.
  • On September 30, 2016, Foamix completed a successful follow-on public equity offering at a price per share of $9.50, raising $58.1 million including the exercise of the underwriters' option (that was exercised in October 2016) to purchase an additional 411,959 shares. Net proceeds to the Company (including from the underwriters' option), after expenses and underwriter fees, totaled $54.1 million.
  • Foamix's intellectual property portfolio continues to expand. The Company currently has 145 patents issued worldwide and 49 patents issued in the United States.

Financial highlights for the three months ended September 30, 2016:

  • Total revenues were $2.5 million compared with $22,000 for the three months ended September 30, 2015. The revenues in the quarter included royalty payments of $794,000 from Bayer HealthCare AG for the sales of Finacea® Foam and additional contingent payments totaling $1.75 million, due to Bayer's achievement of net sales in excess of the target set for this product.
  • Research and development expenses were $5.9 million, compared with $2.0 million in the three months ended September 30, 2015. This increase resulted primarily from an increase in costs relating to the FMX101 and FMX103 clinical trials as well as an increase in payroll and related expenses due to an increase in the number of R&D employees.
  • Selling, general and administrative expenses were $2.6 million, compared with $1.6 million in the three months ended September 30, 2015. The increase in selling, general and administrative expenses resulted primarily from increases in payroll and other payroll-related expenses, market research costs, expenses related to the Company's board of directors (including stock-based compensation) and patent and trademark expenses.
  • Operating expenses totaled $8.5 million, compared with $3.6 million in the three months ended September 30, 2015.
  • Net loss was $5.8 million or $0.19 per share, basic and diluted, compared with a loss of $3.4 million or $0.11 per share, basic and diluted, for the three months ended September 30, 2015.
  • Cash, cash equivalents, short and long-term investments as of September 30, 2016 totaled $140.1 million, compared with approximately $103.8 million as of December 31, 2015.

Financial highlights for the nine months ended September 30, 2016:

  • Total revenues were $4.0 million compared with $579,000 for the nine months ended September 30, 2015. Revenues for the nine months ended September 30, 2016 included mostly royalty payments in the amount of $2.2 million from Bayer HealthCare AG for the sales of Finacea® Foam and additional contingent payments totaling $1.75 million, due to Bayer's achievement of net sales in excess of the target set for this product.
  • Research and development expenses were $16.2 million, compared with $6.9 million in the nine months ended September 30, 2015. The increase in research and development expenses relates to the Company's Phase 3 clinical trials for FMX101, its lead product candidate for treatment of moderate-to-severe acne, the completion of Phase 2 clinical trials for FMX103, the Company's lead product candidate for treatment of papulopustular rosacea, an increase in costs of advisers and consultants relating to R&D clinical trials, as well as an increase in payroll and related expenses due to an increase in the number of R&D employees.
  • Selling, general and administrative expenses were $6.4 million, compared with $5.0 million in the nine months ended September 30, 2015. The increase in selling, general and administrative expenses resulted primarily from an increase in payroll, payroll-related expenses, market research expenses and travel expenses.
  • Operating expenses totaled $18.6 million, compared with $11.4 million in the nine months ended September 30, 2015.
  • Net loss was $18.5 million or $0.60 per share, basic and diluted, compared with a loss of $11.1 million or $0.41 per share, basic and diluted, for the nine months ended September 30, 2015.

Management overview

During the third quarter of 2016 we continued to progress the development of our lead clinical-stage product candidates, FMX101 for the treatment of moderate-to-severe acne, and FMX103 for the treatment of moderate-to-severe papulopustular rosacea.

Regarding FMX101, in early May 2016, we commenced our Phase 3 clinical trials for the treatment of moderate-to-severe acne.

The Phase 3 program consists of two multi-center trials, each with a target enrollment of 450 patients with moderate-to-severe acne.  Patients are being randomized on a 2:1 basis (active vs vehicle), initially into a 12-week double-blind vehicle-controlled phase where patients will be treated once daily with either 4% minocycline foam or vehicle.  The double-blind portion of the studies will be followed by 9 months of open-label treatment with the active 4% foam to evaluate the safety of intermittent use of FMX101. 

The two co-primary efficacy endpoints are (1) the absolute change from baseline in inflammatory lesion counts in each treatment group at week 12; and (2) the proportion of patients achieving success at week 12 as defined by an Investigator's Global Assessment (IGA) score of "clear" or "almost clear" (score of 0 or 1) and at least a 2-grade improvement (decrease) from baseline at week 12. Safety evaluation will include reported adverse events, assessments of tolerability, clinical laboratory tests and vital signs.

Target enrollment for the two Phase 3 trials of FMX101 (900 patients) has been reached.  We will allow for additional patients who are currently in the screening process for the Phase 3 clinical trials to finish that process and also be enrolled. We anticipate final patient enrollment to be completed by the end of November, 2016; and we maintain our expectation to report top-line results from the blinded portion of these trials in the first half of 2017.

FMX101 has the potential to be the first clinically-viable topical formulation of minocycline. This product candidate is being developed in the U.S. under the FDA's abbreviated 505(b)(2) pathway.

FMX103, for the treatment of moderate-to-severe papulopustular rosacea, has the same active ingredient, minocycline, as our lead candidate, FMX101.

In September 2016, we announced the topline results of a Phase 2 clinical trial of FMX103 for the treatment of moderate-to-severe papulopustular rosacea. The double-blind, randomized, placebo-controlled Phase 2 trial included 233 patients with moderate-to-severe rosacea enrolled at 18 sites in Germany. Patients were randomized to receive either 1 of 2 doses of FMX103 minocycline foam (3% or 1.5%) or vehicle foam once daily over 12 weeks, followed up by a 4-week post-treatment evaluation.  Clinically and statistically significant differences were demonstrated for improvement in the efficacy endpoints (reduction in the number of inflammatory lesions papules and pustules, and improvement of Investigator Global Assessment score) for FMX103 compared with the vehicle-treated group.

We intend to meet with the FDA to review the results of our Phase 2 clinical trial of FMX103 and discuss next steps in progressing into a Phase 3 program, which we hope to commence in 2017.

Development activities continue for both FMX102 (minocycline foam for the treatment of impetigo) and FDX104 (doxycycline foam for the management of acne-like rash associated with EGFRI use). We will provide updates on these programs as they materialize. 

During the Q3, 2016 our patent portfolio expanded and we currently have 145 patents issued worldwide and 49 patents issued in the United States.

In addition to our internal drug development pipeline, we have development and license agreements relating to our proprietary foam technology with other pharmaceutical companies, including Bayer Healthcare, Merz, Allergan and Prestium, which was recently acquired by Mylan, in various stages of development and commercialization. Our agreements with these licensees entitle us to development fees, contingent payments and royalties upon commercialization.

In September 2015, Bayer Healthcare began selling Finacea® Foam (azelaic acid 15% for the treatment of rosacea) in the U.S.  Finacea® foam is a prescription foam product which was developed as part of a research and development collaboration between Foamix and Bayer, utilizing Foamix's proprietary foam technology platform. According to our license agreement with Bayer, we are entitled to royalties and certain contingent payments upon commercialization of Finacea Foam. For the three months ended September 30, 2016, we were entitled to royalties from Bayer Healthcare in an amount of $794,000, up 6% from the second quarter of 2016. Furthermore, the Company is entitled to additional payments of $1.75 million due to achievement of certain revenue level by Bayer, based on Bayer's net sales of Finacea® Foam during such period. 

Financial results for the three months ended September 30, 2016

Revenues

Total revenues for the three month ended September 30, 2016 were $2.5 million compared with $22,000 for the three months ended September 30, 2015. The revenues in the quarter included royalty payments from Bayer HealthCare AG for the sales of Finacea® Foam of $794,000 and additional contingent payments totaling $1.75 million, due to Bayer's achievement of net sales in excess of the target set for this product. Revenues for the three months ended September 30, 2015 included payments for development projects with other customers.

Operating Expenses

Our operating expenses for the three months ended September 30, 2016 and 2015 were as follows:

Research and Development Expenses

Research and development expenses increased by $3.9 million, or 195%, from $2.0 million in the three months ended September 30, 2015 to $5.9 million in the three months ended September 30, 2016. The increase in research and development expenses resulted primarily from an increase of $3.3 million in costs relating to the FMX101 and FMX103 clinical trials and an increase of $567,000 in payroll and payroll related expenses due to an increase in the number of R&D employees (including bonuses and stock-based compensation).

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased by $919,000, or 57%, from $1.6 million in the three months ended September 30, 2015 to $2.6 million in the three months ended September 30, 2016. The increase in selling, general and administrative expenses resulted primarily from an increase of $439,000 in payroll and other payroll-related expenses (including bonuses and stock-based compensation) and $296,000 in market research costs; an increase of $72,000 in expenses related to the Company's board of directors (including stock-based compensation) and a $58,000 increase in patent and trademark expenses;

Finance Income, Net

For the three months ended September 30, 2016 we recorded financial income of $193,000 as opposed to financial income of $203,000 recorded for the three months ended September 30, 2015. The financial income in the three months ended September 30, 2016 and 2015 resulted mostly from interest and financial gains from our cash investments.

Net Loss

For the three months ended September 30, 2016 we recorded a loss of $5.8 million or $0.19 per share, basic and diluted, compared with a loss of $3.4 million or $0.11 per share, basic and diluted, for the three months ended September 30, 2015.

Financial results for the nine months ended September 30, 2016

Revenues

Total revenues for the nine months ended September 30, 2016 were $4.0 million compared with $579,000 for the nine months ended September 30, 2015. Revenues for the nine months ended September 30, 2016 included mostly royalty payments in the amount of $2.2 million, from Bayer HealthCare AG for the sales of Finacea® Foam and additional contingent payments totaling $1.75 million, due to Bayer's achievement of net sales in excess of the target set for this product. Revenues for the nine months ended September 30, 2015 included payments for development projects with other customers.

Operating Expenses

Our operating expenses for the nine months ended September 30, 2016 and 2015 were as follows:

Research and Development Expenses

Research and development expenses increased by $9.3 million, or 135%, from $6.9 million in the nine months ended September 30, 2015 to $16.2 million in the nine months ended September 30, 2016. The increase in research and development expenses resulted primarily from an increase of $7.6 million in costs relating to the FMX101 and FMX103 clinical trials; an increase of $1.4 million in payroll and payroll related expenses (including bonuses and stock-based compensation) due to an increase in the number of R&D employees; and an increase of $272,000 in advisory and consulting expenses.

To read full press release, please click here.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES